CardioDx (Palo Alto, CA) a commercial-stage cardiovascular molecular diagnostics company focused on coronary artery disease, cardiac arrhythmia and heart failure, closed a $5M Series D financing, bring the total round to $34.5M. Participants include GE Healthymagination Fund, Kleiner Perkins Caufield & Byers, TPG Biotech, Intel Capital, Mohr Davidow Ventures, DAG Ventures, Pappas Ventures and Asset Management Group.